Optimizing Outcome in ALK-Positive Non-Small Cell Lung Cancer: Using Precision Medicine & Patient Assessments for Personalized First-Line ALK-Targeted Therapy

Optimizing Outcome in ALK-Positive Non-Small Cell Lung Cancer: Using Precision Medicine & Patient Assessments for Personalized First-Line ALK-Targeted Therapy is organized by BioMedical Learning Institute (BMLI).

Start Date: 09/15/2020
Date Expires: 09/15/2021

CME Accreditation:
Physicians:
The BioMedical Learning Institute designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses:
The BioMedical Learning Institute designates this educational activity for 2 contact hours.

Pharmacists:
Credits: 2 hours (0.2 ceu)

Other:
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credit for attending this symposium.

Overview:
This activity has been designed with the assistance of the four expert faculty members and of our BMLI Lung Cancer Planning Committee to help the target audience overcome key challenges and issues involved with devising the optimal treatment plans with ALK TKIs for ALK-positive NSCLC in the first-line setting. It is also intended to help the target audience close personal Quality Performance Practice Gaps while considering a number of critical treatment decision-making factors that have been identified in this Needs Assessment, including systemic efficacy, CNS efficacy, mechanisms of resistance, and molecular testing with ALK TKIs, and, patient needs, patient lifestyles and tolerability with daily, chronic ALK TKI therapy, towards the ultimate goal of improving patient outcomes through improved performance-in-practice by the target audience.

Learning Objectives:
Physician
• Compare and contrast the systemic and CNS efficacy data, and, side effect profiles of the current and emerging ALK TKIs across all lines of therapy to assist in the development of the optimal first-line ALK TKI therapy for ALK-positive NSCLC.
• Understand the importance of knowing the different patients’ needs, perspectives, lifestyles and tolerability for ALK TKI therapy, and, the physician preferences for selecting ALK TKIs in first-line therapy for long-term, daily use in ALK-positive metastatic NSCLC.
• Analyze the mechanisms of Acquired Resistance to ALK TKIs and their implications on selecting optimal first-line ALK TKI therapy for metastatic ALK-positive NSCLC.
• Understand the clinical applications and benefits of using NGS ctDNA and cfDNA testing for detecting ALK-gene fusions in treatment-naïve metastatic ALK-positive NSCLC patients.
• Devise the optimal first-line ALK-TKI treatment plans for ALK-positive metastatic NSCLC patients based upon systemic efficacy, CNS efficacy, adverse events to ALK TKIs, personalized patient tolerability profiles, patient needs and preferences, physician preferences, and, the type of ALK fusion variant.

Nurse
• Describe the systemic and CNS efficacy data, and, side effect profiles of the current and emerging ALK TKIs across all lines of therapy to assist in the development of the optimal first-line ALK TKI therapy for ALK-positive NSCLC.
• Recognize the importance of knowing the different patients’ needs, perspectives, lifestyles and tolerability for ALK TKI therapy, and, the physician preferences for selecting ALK TKIs in first-line therapy for long-term, daily use in ALK-positive metastatic NSCLC.
• List the mechanisms of Acquired Resistance to ALK TKIs and their implications on selecting optimal first-line ALK TKI therapy for metastatic ALK-positive NSCLC.
• Identify the clinical applications and benefits of using NGS ctDNA and cfDNA testing for detecting ALK-gene fusions in treatment-naïve metastatic ALK-positive NSCLC patients.
• Recall how to develop the optimal first-line ALK-TKI treatment plans for ALK-positive metastatic NSCLC patients based upon systemic efficacy, CNS efficacy, adverse events to ALK TKIs, personalized patient tolerability profiles, patient needs and preferences, physician preferences, and, the type of ALK fusion variant.

Pharmacist
• Describe the systemic and CNS efficacy data, and, side effect profiles of the current and emerging ALK TKIs across all lines of therapy to assist in the development of the optimal first-line ALK TKI therapy for ALK-positive NSCLC.
• Recognize the importance of knowing the different patients’ needs, perspectives, lifestyles and tolerability for ALK TKI therapy, and, the physician preferences for selecting ALK TKIs in first-line therapy for long-term, daily use in ALK-positive metastatic NSCLC.
• List the mechanisms of Acquired Resistance to ALK TKIs and their implications on selecting optimal first-line ALK TKI therapy for metastatic ALK-positive NSCLC.
• Identify the clinical applications and benefits of using NGS ctDNA and cfDNA testing for detecting ALK-gene fusions in treatment-naïve metastatic ALK-positive NSCLC patients.
• Recall how to develop the optimal first-line ALK-TKI treatment plans for ALK-positive metastatic NSCLC patients based upon systemic efficacy, CNS efficacy, adverse events to ALK TKIs, personalized patient tolerability profiles, patient needs and preferences, physician preferences, and, the type of ALK fusion variant.